# Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update
Canonical URL: https://biopharmsignal.com/news/IRON/disc-medicine-reports-first-quarter-2026-financial-results-and-provides-business-update
Ticker: IRON
Company: Disc Medicine
Source: Disc Medicine
Published: 2026-05-05 12:30 EST
Original Source URL: https://ir.discmedicine.com
## Summary

Completed enrollment of the Phase 3 APOLLO study of bitopertin in erythropoietic protoporphyria (EPP); topline data expected in Q4 2026 Updated data from Phase 2 study of DISC-0974 in patients with anemia of myelofibrosis (MF) to be shared at the American Society of Clinical Oncology (ASCO) Annual

## Article Body
Completed enrollment of the Phase 3 APOLLO study of bitopertin in erythropoietic protoporphyria (EPP); topline data expected in Q4 2026 Updated data from Phase 2 study of DISC-0974 in patients with anemia of myelofibrosis (MF) to be shared at the American Society of Clinical Oncology (ASCO) Annual
## Recent Company News
- 2026-06-02 12:00 EST — [Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting](https://biopharmsignal.com/news/IRON/disc-medicine-presents-updated-positive-data-from-rally-mf-phase-2-trial-in-patients-with-myelofibrosis-mf-and-anemia-at-the-2026-american-society-of-clinical-oncology-asco-annual-meeting) — Source: Disc Medicine
- 2026-06-01 12:30 EST — [Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients](https://biopharmsignal.com/news/IRON/disc-medicine-launches-expanded-access-program-for-bitopertin-for-epp-patients) — Source: Disc Medicine
- 2026-05-12 13:30 EST — [Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress](https://biopharmsignal.com/news/IRON/disc-medicine-announces-multiple-presentations-across-portfolio-at-the-european-hematology-association-eha-2026-congress) — Source: Disc Medicine
- 2026-05-05 12:30 EST — [Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/IRON/disc-medicine-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: Disc Medicine
- 2026-04-21 14:00 EST — [Disc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 Trial of DISC-0974 in Patients with Myelofibrosis and Anemia at the American Society of Clinical Oncology (ASCO) Annual Meeting](https://biopharmsignal.com/news/IRON/disc-medicine-announces-oral-presentation-of-data-from-rally-mf-phase-2-trial-of-disc-0974-in-patients-with-myelofibrosis-and-anemia-at-the-american-society-of-clinical-oncology-asco-annual-meeting) — Source: Disc Medicine
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)